A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer

Amanda E. Hird, Diana E. Magee, Bimal Bhindi, Xiang Y. Ye, Thenappan Chandrasekar, Hanan Goldberg, Laurence Klotz, Neil Fleshner, Raj Satkunasivam, Zachary Klaassen, Christopher J.D. Wallis

Research output: Contribution to journalReview article

Abstract

This systematic review supports the use of non-steroidal anti-androgens in high-risk non-metastatic castrate-resistant prostate cancer. Indirect comparison suggests there are important differences in oncologic outcomes between agents. Treatment selection will depend on patient and physician appraisal of the relative efficacy and toxicity of each agent.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Drug-related side effects and adverse reactions
  • Nonsteroidal anti-androgens
  • Prostatic neoplasms
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Hird, A. E., Magee, D. E., Bhindi, B., Ye, X. Y., Chandrasekar, T., Goldberg, H., Klotz, L., Fleshner, N., Satkunasivam, R., Klaassen, Z., & Wallis, C. J. D. (Accepted/In press). A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2020.02.005